Surgical equipment maker CONMED will hold a results call at 4:30 p.m. ET on Oct. 28.
CONMED Corporation announced it will report its third-quarter 2026 financial results after market close on October 28, 2026. The company's management will host a conference call at 4:30 p.m. ET on the same day to discuss the results. Interested parties can participate via live webcast or telephone.
CONMED Corporation to Report Third Quarter 2026 Financial Results on October 28, 2026
CONMED Corporation (NYSE: CNMD) announced it will release its third-quarter 2026 financial results after market close on Wednesday, October 28, 2026. The company will host a conference call at 4:30 p.m. ET on the same day to discuss these results. Interested parties can participate via live webcast or telephone, with replay available on their investor relations website.
CONMED Corporation (CNMD) Stock forecasts
This article provides stock forecasts for CONMED Corporation (CNMD). The content appears to be a stub or an error page from Yahoo Finance, displaying navigation and general financial market information rather than specific analysis or predictions for CNMD. It indicates that the UK markets are closed and shows various market indices and currency rates.
CONMED Corporation (CNMD) Stock forecasts
Argus has lowered its target price for CONMED Corporation (CNMD) to $48.00, citing the medical equipment company's focus on sports medicine and general surgeries. The current stock price for CNMD is $45.18. The report, published on September 23, 2026, provides a summary of the company's business activities.
Bank of America Corp DE Acquires Shares of 1,341,409 CONMED Corporation $CNMD
Bank of America Corp DE has acquired a new stake of 1,341,409 shares in CONMED Corporation, valued at approximately $43.9 million, giving it a 4.48% ownership. Despite this significant investment, analyst sentiment remains cautious with a consensus "Reduce" rating and a price target of $41.40 for CONMED. The medical technology company recently exceeded quarterly expectations with EPS of $1.38 and revenue of $343.5 million, though its stock opened down 1.3% at $44.84.
Conmed Corp (EC8.MU) Analyst Insights, Price Targets & Recommendations
This article provides an overview of analyst insights for Conmed Corp (EC8.MU), including recent reiterations, initiations, and downgrades from various financial institutions. The stock is currently trading at 40.00 EUR, down 0.50% as of the last update. It lists several analyst actions from July, June, and May 2026, indicating a mixed sentiment ranging from Neutral to Underperform.
(CNMD) Movement as an Input in Quant Signal Sets
This article provides an in-depth quantitative analysis of Conmed Corp. (NASDAQ: CNMD), highlighting a neutral near-term sentiment with potential for moderate mid-term weakness. It identifies an exceptional short setup with a 48.6:1 risk-reward ratio, targeting a 14.2% downside. The analysis offers three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, along with multi-timeframe signal analysis.
CONMED Corporation (NYSE:CNMD) Receives Average Recommendation of "Reduce" from Brokerages
CONMED Corporation (NYSE:CNMD) has received an average "Reduce" rating from eight analysts, with two recommending "sell" and six "hold." Despite exceeding quarterly earnings expectations with an EPS of $1.38 and revenue of $343.49 million, the average 12-month price target is $41.40, below its current share price of $46.15. Institutional investors like BlackRock and Bank of America have recently increased their positions in the company, while the California State Teachers’ Retirement System significantly boosted its stake.
CONMED (CNMD) Stock Price, News & Analysis
CONMED Corporation (NYSE:CNMD) is a medical technology company specializing in surgical devices and equipment. The stock currently has a "Reduce" consensus rating from analysts, with a target price suggesting a potential downside. Key stats indicate a market capitalization of $1.40 billion and a P/E ratio of 25.26, while the company does not pay a dividend.
CONMED Director Kim Kelderman Awarded 500 RSUs Under 2025 Long-Term Incentive Plan
CONMED Corp (NASDAQ:CNMD) director Kim Kelderman was granted 500 restricted stock units (RSUs) on September 8, 2026, as part of the company's 2025 Long-Term Incentive Plan. The RSUs, acquired at a $0 price, vest 100% after one year, bringing Kelderman's direct ownership to 500 common shares. This transaction was reported in a Form 4 filing on September 10, 2026.
CONMED at Wells Fargo conference: growth story gains momentum
CONMED Corporation (CNMD) presented at the Wells Fargo 21st Annual Healthcare Conference, highlighting its accelerating growth driven by minimally invasive surgery, international expansion, and margin improvements. The company expects second-half 2026 revenue growth to accelerate to 6-8%, supported by key products like AirSeal, BioBrace, and Buffalo Filter, while also prioritizing de-leveraging and strategic tuck-in acquisitions. Management emphasized CONMED's transition from a stable mid-single-digit grower to a faster-moving company with enhanced operating leverage and strong free cash flow generation.
CONMED (CNMD) director receives 500 shares as stock units vest
CONMED director Kim Kelderman converted 500 restricted stock units (RSUs) into 500 common shares on September 8, 2026. This transaction was part of his equity compensation under CONMED's 2025 Long-Term Incentive Plan, with the RSUs generally vesting 100% after one year. Following the conversion, Kelderman directly holds 500 common shares and 0 RSUs.
291,203 Shares in CONMED Corporation $CNMD Acquired by Bank of New York Mellon Corp
Bank of New York Mellon Corp has acquired 291,203 shares of CONMED Corporation (NYSE:CNMD), valued at approximately $9.5 million, representing about 0.97% of the company. Other institutional investors like AQR Capital Management and Intech Investment Management also increased their stakes, while Creative Planning initiated a new position. Despite CONMED beating quarterly earnings estimates with $1.38 EPS and $343.5 million in revenue, analysts maintain a "Reduce" rating with a consensus price target of $41.40.
BlackRock Inc. Invests $157.78 Million in CONMED Corporation $CNMD
BlackRock Inc. has invested approximately $157.78 million in CONMED Corporation, acquiring 4.82 million shares and taking a 16.1% stake in the medical technology company. This investment comes as CONMED exceeded its quarterly earnings expectations, reporting adjusted EPS of $1.38 and revenue of $343.5 million, and provides a fiscal 2026 EPS guidance of $4.48–$4.60. Despite this significant institutional interest, analyst sentiment remains cautious, with a consensus "Reduce" rating and a target price of $41.40.
Technical Reactions to CNMD Trends in Macro Strategies
This article provides a technical analysis of Conmed Corp. (NASDAQ: CNMD), highlighting weak near-term sentiment that may lead to a resumption of long-term weakness. It presents institutional trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis and support/resistance levels.
Conmed (CNMD) Up 7.1% Since Last Earnings Report: Can It Continue?
Conmed (CNMD) shares have risen 7.1% since its last earnings report, outperforming the S&P 500. The company reported strong Q2 2026 earnings and revenues, beating estimates, with organic sales gaining momentum, particularly in international markets and Orthopedic Surgery. Despite some declines in General Surgery due to GI portfolio exits, the company has updated its 2026 guidance with a higher projected EPS.
CONMED Corporation to Participate in the Wells Fargo 21st Annual Healthcare Conference
CONMED Corporation (NYSE: CNMD) announced its participation in the Wells Fargo 21st Annual Healthcare Conference, scheduled for September 8-10, 2026. Management will host a fireside chat on September 9th at 1:30 p.m. Eastern Time, which will be accessible via a live audio webcast and a subsequent replay on the company's investor relations website.
CONMED offers a live webcast and about 90 days of replay access
CONMED Corporation (NYSE: CNMD) announced its participation in the Wells Fargo 21st Annual Healthcare Conference, scheduled for September 8-10, 2026, in Everett, MA. Management will participate in a fireside chat on September 9th at 1:30 p.m. Eastern Time. A live audio webcast will be available on the company's investor relations website, with a replay accessible for approximately 90 days.
3 Reasons to Avoid CNMD and 1 Stock to Buy Instead
This article advises investors to avoid CONMED (CNMD) despite its recent market performance, citing three main reasons: weak constant currency growth, limited distribution channels due to its small size, and slim projected revenue growth. The author suggests that while CNMD's valuation is reasonable, its shaky fundamentals present too much downside risk and recommends considering other, more entrenched companies.
CONMED (NYSE:CNMD) Draws Focus After Strong Results
CONMED Corporation (NYSE:CNMD) is drawing market attention due to its strong quarterly financial performance, operational improvements, and sustained demand for its surgical technology solutions. The company's focus on advanced medical technologies and its diversified product portfolio, catering to various medical specialties, have contributed to its growth. Despite mixed market sentiment regarding valuation, CONMED's innovation and financial discipline are strengthening its position in the healthcare industry.
CONMED Corporation (NYSE:CNMD) Given Average Rating of "Reduce" by Brokerages
CONMED Corporation (NYSE:CNMD) has received an average "Reduce" rating from eight brokerages, with an average 12-month price target of $41.40, despite exceeding quarterly expectations with adjusted EPS of $1.38 and revenue of $343.49 million. Shares opened at $51.34, significantly above the analyst consensus, and several institutional investors, including BlackRock and Bank of America, have recently acquired substantial positions in the company.
Here's Why You Should Retain CONMED Stock in Your Portfolio Now
CONMED Corporation (CNMD) is poised for growth due to strong adoption of its high-margin platforms like AirSeal, Buffalo Filter, and BioBrace, along with increasing robotic procedure volumes and ASC penetration. The company's organic sales growth is healthy, particularly in Orthopedic Surgery and driven by regulatory tailwinds for Buffalo Filter and the growth of BioBrace. However, challenges include moderating AirSeal growth expectations and ongoing tariff headwinds that impact earnings despite a recent refund.
CONMED Corporation $CNMD Stock Holdings Lessened by Amundi
Amundi significantly reduced its stake in CONMED Corporation (NYSE:CNMD) by 99.7% in the first quarter, selling over 2.29 million shares. Despite this, other major investors increased their holdings, and CONMED surpassed earnings and revenue expectations. However, analysts maintain a cautious "Reduce" rating with a price target below the current stock price.
CONMED (NYSE:CNMD) Upgraded to Hold at Zacks Research
Zacks Research has upgraded CONMED (NYSE:CNMD) from a "strong sell" to a "hold" rating, despite the broader analyst consensus remaining at "Reduce" with an average price target of $41.40. This upgrade follows CONMED's strong quarterly earnings report, where it exceeded EPS and revenue estimates, with EPS of $1.38 against an estimated $1.11, and revenue of $343.49 million versus the $337.60 million consensus. Several institutional investors also increased their holdings in CONMED during the first quarter.
CONMED Corporation $CNMD Shares Sold by Bank of America Corp DE
Bank of America Corp DE significantly reduced its stake in CONMED Corporation ($CNMD) by 57.6% in the first quarter, selling 1.9 million shares but still retaining 1.4 million shares valued at approximately $49.6 million. Despite CONMED beating Q1 earnings estimates with $1.38 EPS and revenue of $343.5 million, analyst sentiment remains cautious, with a consensus "Reduce" rating and an average price target below its current trading price. Other institutional investors like Vanguard and Dimensional Fund Advisors have adjusted their holdings, with some increasing and others initiating new positions.
Conmed Corp (CNMD) Stock News Today
This page provides an overview of Conmed Corp (CNMD) stock information, including its current market price, market capitalization, and P/E ratio. It also indicates that more news and analysis regarding the company's stock, earnings, and analyst ratings will be available soon. The platform, TradingKey, offers tools for investment decisions and advises users that the information provided is general and not financial advice.
Conmed Corp (CNMD) Earnings Forecast: Future EPS & Revenue Growth Estimates
Conmed Corp (CNMD) has an earnings forecast score of 5.71, ranking 183 out of 200 in its industry, with an average analyst price target of $52.00. Analysts currently recommend a "Hold" rating for the stock. The company's expected revenue for the next quarter is $336.23M, and its previous quarter's EPS was $0.45, with an expectation of $1.00 for the upcoming quarter.
CONMED Corporation (CNMD) Stock Forecasts
Argus has raised its target price for CONMED Corporation (CNMD) to $53.00. The medical equipment company, based in Utica, New York, specializes in sports medicine procedures and general surgeries. The current stock price for CNMD is $49.12.
CONMED Corporation $CNMD Shares Sold by Edgestream Partners L.P.
Edgestream Partners L.P. significantly reduced its stake in CONMED Corporation (NYSE:CNMD) during the first quarter, selling 87.4% of its shares. Despite this, CONMED reported strong quarterly earnings, surpassing analyst expectations for both EPS and revenue, and maintained its fiscal 2026 EPS guidance. Analyst sentiment for CONMED remains cautious, with a consensus "Reduce" rating and an average price target of $41.40.
CONMED Corp Q2 2026: Revenue $343.5M, EPS $0.77— 10-Q Summary
CONMED Corp reported its Q2 2026 financial results, with revenue reaching $343.5 million, remaining relatively flat year-over-year. The company saw an increase in net income to $23.1 million and diluted earnings per share to $0.77. Growth was primarily driven by orthopedic sales, despite the company's exit from the gastroenterology market.
Bank of New York Mellon Corp Decreases Stock Holdings in CONMED Corporation $CNMD
Bank of New York Mellon Corp significantly reduced its stake in CONMED Corporation (NYSE:CNMD) by 51.9% in the first quarter, selling 312,691 shares and now owning 289,234 shares valued at $10.23 million. Other institutional investors also adjusted their positions in CONMED, with some increasing and others decreasing their holdings. The article also provides recent analyst ratings, price targets, and discusses CONMED's positive Q2 results and increased guidance, despite some neutral and negative sentiment regarding its valuation and modest revenue growth.
Stocks making big moves this week: Huron, Sherwin-Williams, PROG, CONMED, and Freshworks
This article highlights five companies – Huron, Sherwin-Williams, PROG, CONMED, and Freshworks – that experienced significant stock movements this week due to strong financial results, raised outlooks, or key appointments. Huron, Sherwin-Williams, and CONMED saw their stocks rise after beating analyst expectations and increasing their full-year guidance. PROG Holdings' stock fell despite beating expectations and raising guidance, while Freshworks rose after announcing a new Chief Product and Technology Officer.
Conmed Corp : JP Morgan Raises Target Price t
This article reports that JP Morgan has increased its target price for Conmed Corp. The specific details of the new target price and the rationale behind the upgrade are not provided in the snippet.
CONMED (NYSE:CNMD) Given New $46.00 Price Target at Wells Fargo & Company
Wells Fargo & Company has raised its price target for CONMED (NYSE:CNMD) to $46.00 from $39.00 while maintaining an "equal weight" rating. This adjustment follows CONMED's strong Q2 2026 earnings, where the company surpassed consensus estimates for both EPS and revenue, and provided optimistic full-year guidance. Despite a reported revenue growth of only 0.3%, organic sales increased by 6% after excluding the impact of strategic product exits.
CONMED CORP : JEFFERIES RAISES TARGET PRICE TO $49 FROM $40
Jefferies has raised its target price for CONMED CORP (CNMD.N) to $49 from $40. This article, published by Reuters, briefly reports on this updated analyst rating. The content is for informational purposes and not intended as investment advice.
CONMED Q2 Earnings and Revenues Beat Estimates, Gross Margin Expands
CONMED Corporation (CNMD) reported strong second-quarter 2026 results, with adjusted EPS of $1.38 and revenues of $343.5 million, both exceeding Zacks Consensus Estimates. The company saw organic constant-currency revenue growth of 6% driven by its AirSeal, Buffalo Filter, and BioBrace platforms, and an adjusted gross margin expansion to 59.5%. Despite some headwinds like the GI portfolio exit and flat domestic orthopedic sales, CONMED raised its adjusted EPS outlook for 2026, anticipating continued organic growth.
Conmed: Q2 Earnings Snapshot
This article provides a Q2 earnings snapshot for Conmed. No specific financial details or further information are available within the provided content.
CONMED (NYSE: CNMD) lifts Q2 profit, exits gastro line and cuts notes
CONMED Corporation reported increased net income and diluted EPS for Q2 2026, reaching $23.1 million and $0.77 respectively, despite largely flat net sales year-over-year. The company's gross margin expanded to 57.5%, boosted by an IEEPA tariff refund, though partially offset by inventory write-downs due to discontinued gastroenterology products. CONMED also repurchased a significant portion of its convertible notes, funding this through a new term loan and revolver borrowings, while suspending dividend payments and exiting its gastroenterology business.
Conmed: Q2 Earnings Snapshot
Conmed reported its Q2 earnings, with net income totaling $4.8 million, or $0.16 per share. The medical technology company's adjusted earnings were 65 cents per share, surpassing Wall Street expectations. Revenue reached $326.6 million, also exceeding analyst forecasts.
CONMED updates 2026 adjusted EPS outlook to $4.48-$4.60 after Q2
CONMED Corporation reported strong second-quarter 2026 financial results, with sales of $343.5 million and adjusted diluted EPS of $1.38, exceeding expectations. The company updated its full-year 2026 financial guidance for adjusted diluted EPS to range from $4.48 to $4.60, reflecting its Q2 performance and an updated outlook for the remainder of the year. This improved outlook is attributed to organic constant currency net sales growth across both Orthopedic Surgery and General Surgery product lines, and strategic portfolio optimization.
CONMED Corporation Reports Second Quarter 2026 Financial Results; Updates Full Year 2026 Guidance
CONMED Corporation reported its second quarter 2026 financial results, with sales of $343.5 million, a 0.3% year-over-year increase, and adjusted diluted EPS up 20.0% to $1.38. The company updated its full-year 2026 financial guidance, anticipating net sales between $1.358 billion and $1.373 billion, and adjusted diluted EPS between $4.48 and $4.60. Key operational announcements included new board and CFO appointments, and an expanded indication for its AirSeal® Robotic Solution.
CONMED earnings ahead as investors weigh strategic sale prospects By Investing.com
CONMED Corporation is expected to report second-quarter earnings, with analysts anticipating $1.11 per share on $337.5 million in revenue. The medical device maker is also exploring a potential sale, which Bloomberg reported in mid-July, causing shares to rise significantly. Investors will be closely watching management's commentary on the strategic review and the company's ability to demonstrate organic growth in key platforms.
CONMED Number of Employees 2026 | Employee Count & Headcount Data
CONMED Corp. (CNMD) has approximately 3,868 employees worldwide as of March 2026, marking a 0.2% decline from 2023. The company, headquartered in Largo, Florida, is actively hiring with 212 job postings in 2026, and its workforce is primarily concentrated in the United States. Employee sentiment is neutral but declining, with an average salary of $88,679 globally.
Conmed Corp (CNMD) Cash Flow
This article provides a detailed historical cash flow statement for Conmed Corp (CNMD), covering quarterly and annual data for operating, investing, and financing activities. It also includes definitions and explanations of key cash flow terms like operating cash flow, investing cash flow, financing cash flow, and free cash flow, along with recent figures for CNMD. The data helps evaluate the company's financial soundness and stability.
Conmed Corp (CNMD) Institutional Confidence
Conmed Corp (CNMD) has an institutional shareholding score of 10.00, placing it first in the Healthcare Equipment & Supplies industry. The institutional shareholding proportion has seen a quarter-over-quarter decrease of 16.04%, with HOTCHKIS & WILEY as the largest institutional holder, possessing 1.05% of outstanding shares. Various institutional investors have adjusted their holdings, with some increasing and others decreasing their stakes.
Conmed Corp (CNMD) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Conmed Corp (CNMD), listing major institutional holders and their respective proportions. It also presents a breakdown of shareholder types such as investment advisors and hedge funds, as well as institutional shareholding activity over several quarters. Additionally, the article identifies related ETFs that hold CNMD shares.
Conmed Corp (CNMD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for Conmed Corp (CNMD), categorizing its revenue by business segment and geographical region. For the reported period, General Surgery accounted for 58.20% of total revenue, while Orthopedic Surgery contributed 41.80%. Geographically, the United States was the largest revenue generator at 56.34%, followed by Europe & Middle East & Africa and Asia Pacific.
Conmed Corp (CNMD) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Conmed Corp (CNMD), indicating a current earnings forecast score of 6.00 and ranking 174 out of 200 in its industry. Analysts have set an average price target of $52.00, with a consensus "Hold" rating. The report also details expected revenue, past and future EPS, and peer comparisons.
CNMD|Conmed Corp|Price:43.500|Chg%:+0.820
This article provides a comprehensive stock analysis of Conmed Corp (CNMD), highlighting its stable fundamentals, high growth potential, and fair valuation within the Healthcare Equipment & Supplies industry. It notes strong institutional ownership, recent "Hold" ratings from analysts with a target price of $38.80, and a sideways trading pattern suggesting suitability for range-bound swing trading. The analysis also covers the company's product lines in orthopedic and general surgery, its high dividend payout, and institutional selling trends.
CNMD|Conmed Corp|Price:42.730|Chg%:+1.460
This article provides a detailed financial overview of Conmed Corp (CNMD), including its stock price, market capitalization, P/E ratio, and upcoming earnings date. It presents a comprehensive look at the company's financial indicators such as EPS, revenue, net profit, margins, and debt-to-assets ratio across multiple quarters and fiscal years. The report also includes FAQs offering quick answers to key financial metrics based on the FY2025 earnings report.
